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(57) ABSTRACT 
The present invention provides a general method to retard 
the precipitation inception time for poorly Water-soluble 
camptothecin analogues from a supersaturated solution by a 
chemical conversion approach via pH alteration. This 
method is successfully utilized to prepare stable parenteral 
formulations for silatecan 7-t-butyldimethylsilyl-10 
hydroxycamptothecin (DB-67), a poorly Water-soluble lipo 
philic camptothecin analogue, in aqueous solutions contain 
ing [3-cyclodextrin sulfobutyl ether (SBE-CD) or other 
solubiliZing agents. The formulations manufactured by this 
method are more simple and cost-effective, of higher doses 
and better quality in terms of manufacture loss and formu 
lation stability, and can be free of organic solvents (e.g., 
DMSO or N-methyl-2-pyrrolidinone). 
55 Claims, 6 Drawing Sheets 
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PHARMACEUTICAL FORMULATION FOR 
POORLY WATER SOLUBLE 
CAMPTOTHECIN ANALOGUES 
This application claims the bene?t of US. Provisional 
Patent Application Serial No. 60/311,570 ?led Aug. 10, 
2001. 
This invention Was made With Government support 
under NCI Contract N01-CM-77108. The Government may 
have certain rights in this invention. 
TECHNICAL FIELD 
The present invention relates to the ?eld of compositions 
for treatment of a cancer in an animal. In particular, the 
present invention relates to a method for formulating an 
aqueous solution of a poorly Water-soluble lipophilic camp 
tothecin or camptothecin analog, and to compositions for 
mulated thereby. 
BACKGROUND OF THE INVENTION 
Successful formulation of many neW drug candidates in a 
parenteral or oral dosage form is often limited by loW 
solubilities of these drugs in an aqueous solution and/or 
physical-and chemical instability over a relevant time 
period. In recent years, progress has been made in develop 
ing various solubiliZation formulation approaches, including 
salt formation, cosolvent, complexation, mixed micelles/ 
liposomes, emulsions, and micro/nanoparticles. HoWever, 
for some very poorly Water-soluble drugs, solubiliZation 
approaches are not suf?cient to achieve a desired dosage and 
a supersaturated solution of drugs stable during parenteral or 
oral administration may be one of feW alternatives. 
The inhibition of tumor cell groWth by camptothecin 
analogues is believed to be linked to their action on DNA 
topoisomerases. Structure-activity studies shoW that suc 
cessful inhibition of DNA topoisomerase I by camptothecin 
analogues requires an intact lactone ring (E-ring, species I in 
FIG. 1.) functionality. Camptothecin analogues having open 
lactone ring structures (carboxylate form), While quite 
soluble in Water, are poorly accumulated by cancer cells, 
exhibit limited activity against the topoisomerase enZyme, 
and may be more toxic to healthy cells than the lactone form. 
Unfortunately, the E-ring intact lipophilic camptothecin 
analogues have a very poor solubility in Water. In the past, 
poor solubility has prevented the extensive use of highly 
lipophilic camptothecin analogues in clinical treatment of 
cancer even though lipophilic camptothecin analogues pro 
vide several important advantages over their Water-soluble 
counterparts, such as relatively superior tissue penetration/ 
retention, bioavailability, more consistently optimiZed dos 
age and schedule for administration, and less interpatient 
variability. Indeed, While a number of Water soluble camp 
tothecin derivatives including. Camptosar, topotecan, 
9-amino-camptothecin, 7-(4-methylpiperaZinomethylene) 
10,11-methylenedioxy camptothecin, 10,11 
methylenedioxy-camptothecin and 10,11-ethylenedioxy 
camptothecin have either been on the market, studied 
preclinically, or used in clinical trials to treat certain types of 
human cancer, feW clinical studies in human patients involv 
ing poorly Water soluble, highly lipophilic camptothecin 
analogs [e.g., camptothecin, 10-hydroxy-7-ethyl camptoth 
ecin (SN38), and silatecan 7-t-butyldimethylsilyl-10 
hydroxycamptothecin (DB-67)] have been conducted. This 
is largely attributed to the difficulty in developing pharma 
ceutical formulations that alloW the direct administration of 
the poorly Water-soluble, active camptothecin lactone spe 
cies to human patients With cancer. 
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Silatecan 7-t-butyldimethylsilyl-10 
hydroxycamptothecin (DB-67) is an experimental drug 
under consideration for clinical testing by the National 
Cancer Institute for cancer chemotherapy. As shoWn in FIG. 
1, DB-67 is one of a class of A and B ring modi?ed 
camptothecin analogs. Because of its increased lipophilicity 
and dual 7-alkylsilyl and 10-hydroxy substitution, DB-67 
displays superior binding to cellular and liposomal mem 
branes and enhanced drug stability in the presence of human 
serum albumin When compared With clinically relevant, 
more hydrophilic camptothecin analogues. In vitro cytotox 
icity assays indicate that DB-67 is of comparable potency to 
other FDA approved camptothecin analogs (e.g., Camptosar 
and Hycamtin). A viable formulation for intravenous deliv 
ery of DB-67 should maintain a desired dose (1—3 mg/mL) 
exclusively in the lactone form and of optimal physical and 
chemical stability. 
SUMMARY OF THE INVENTION 
In accordance With the purposes of the present invention 
as described herein, a novel method for formulating an 
aqueous solution of a lipophilic camptothecin or camptoth 
ecin analog, and compositions formulated thereby, are pro 
vided. In one aspect, the present invention provides a 
method for preparing a stable supersaturated solution of a 
lipophilic camptothecin or a camptothecin analog, compris 
ing formulating an alkaline solution of the lipophilic camp 
tothecin or camptothecin analog, and acidifying the alkaline 
solution in the presence of a solubiliZing agent. The alkaline 
solution may be formulated to have a pH of greater than 
about 10.0. 
The alkaline camptothecin or camptothecin analog may 
be acidi?ed by diluting into an acidic solution in the pres 
ence of a solubiliZing agent to achieve a ?nal pH of up to 
about 6.0. Desirably, the acidic solution may include a buffer 
suitable for maintaining a pH of said acidic solution at up to 
about 6.0, for example buffers selected from the group of 
buffers consisting of, but not limited to, citrate, acetate, 
lactate, or any mixture thereof. 
The solubiliZing agent may be selected from a group 
consisting of a cyclodextrin, a liposome, thermodynamically 
stable colloidal dispersions (e.g. micelles or 
microemulsions) containing surface-active agents, an 
emulsion, or any mixture thereof. Typically, the cyclodextrin 
solubiliZing agent may be a Water-soluble [3-cyclodextrin 
derivative, selected from the group consisting of sulfobutyl 
ether [3-cycllodextrin, 2-hydroxypropyl [3-cyclodextrin, any 
other suitably chemically modi?ed [3-cyclodextrin, and any 
mixture thereof. When liposomes are selected as the solu 
biliZing agent, typically they Will be formulated as an acidic 
liposomal suspension having a pH of up to about 6.0. 
Suitable thermodynamically stable colloidal dispersions 
may be formulated to have a pH of up to about 6.0, and may 
comprise a mixture of a surfactant lipid such as Cremophor 
EL, Vitamin E TPGS, various Pluronics (e.g., polyethylene 
oxide/polypropylene oxide polymers, TWeen 80), and the 
like. The dispersions may also contain a Water miscible 
co-solvent selected from the group consisting of ethanol, 
polyethylene glycol (PEG), propylene glycol (PG), glycerol, 
or any mixture thereof. Dextrose or other suitable excipients 
may be added to adjust tonicity. 
Typically, the lipophilic camptothecin or camptothecin 
analog may be camptothecin, silatecan 7-t 
butyldimethylsilyl-10-hydroxycamptothecin, 10-hydroxy-7 
ethyl camptothecin, 9-nitrocamptothecin, silatecan 7-t 
butyldimethylsilyl-camptothecin, 7-methylcamptothecin, 
US 6,653,319 B1 
3 
7-ethylcamptothecin, 7-propylcamptothecin, 
7-butylcamptothecin, or mixtures thereof. 
In another aspect, a method for preparing a stable super 
saturated solution of a lipophilic camptothecin or a 
camptothecin-analog is provided, comprising the steps of 
solubiliZing the camptothecin or camptothecin analog of 
choice in an alkaline solution, and diluting the alkaline 
solution containing the solubiliZed camptothecin or camp 
tothecin analog into an acidic solution in the presence of a 
solubiliZing agent, selected from the solubiliZing agents as 
described above. The properties of the alkaline and acidic 
solutions are as described above. The desired solubiliZing 
agent may be added to the alkaline solution prior to diluting 
the-alkaline solution into the acidic solution, or may be 
dissolved into the acidic solution. 
The alkaline solution may contain an amount of base (for 
example, sodium hydroxide) approximately double the con 
centration of lipophilic camptothecin or camptothecin ana 
log. Typically, the acidic solution Will contain an amount of 
strong acid, such as for example hydrochloric acid, suf?cient 
to neutraliZe the alkaline solution containing camptothecin 
or camptothecin analog. Buffers may be included in the 
acidic solution as described above. Advantageously, the 
method as described provides a stable, supersaturated com 
position of lipophilic camptothecin or camptothecin analog 
Which may be lyophiliZed for long-term storage Without 
signi?cant loss of drug activity upon reconstitution. 
In yet another aspect of the present invention, a compo 
sition suitable for parenteral or oral administration for the 
treatment of a cancer in an animal is provided, comprising 
an aqueous solution containing a therapeutically suf?cient 
amount of a lipophilic camptothecin or camptothecin analog 
formulated as described above and including the lipophilic 
camptothecin or camptothecin analog and a solubiliZing 
agent. The lipophilic camptothecin or camptothecin analog 
may be included in the composition of the present invention 
in an amount of from about 0.5 to about 3 mg/mL of 
solution. 
The cyclodextrin and/or liposome solubiliZing agents may 
be included in the composition in an amount of from about 
10% to about 40% (W/v). In the case Where a thermody 
namically stable colloidal dispersion (e.g. micelles or 
microemulsions) is used as the solubiliZing agent, an aque 
ous solution comprising about 12.5% v/v of a polyethoxy 
lated lipid such as Cremophor EL and 12.5% v/v ethanol 
may be included. In the case Where a liposome is used as a 
solubiliZing agent, an acidic liposomal suspension may be 
used, containing lipids selected from the group consisting of 
egg phospholipids, cholesterol, 
dimyristoylphosphatidylcholine, 
dimyristoylphosphatidylglycerol, or any other suitable lipids 
or mixtures thereof. 
The compositions manufactured by the method of the 
present invention are advantageously more simple and cost 
effective to manufacture, provide a therapeutically suitable 
dose of poorly Water soluble camptothecin or camptothecin 
analog, are stable during storage, and may be formulated to 
be free of undesirable organic solvents (e.g., DMSO or 
N-methyl-2-pyrrolidinone). Advantageously, the composi 
tions may be lyophiliZed for long-term storage Without 
signi?cant loss of drug activity upon reconstitution for 
parenteral or oral administration. 
Other objects and applications of the present invention 
Will become apparent to those skilled in this art from the 
folloWing description Wherein there is shoWn and described 
a preferred embodiment of this invention, simply by Way of 
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illustration of the modes currently best suited to carry out the 
invention. As it Will be realiZed, the invention is capable of 
other different embodiments and its several details are 
capable of modi?cation in various, obvious aspects all 
Without departing from the invention. Accordingly, the 
draWings and descriptions Will be regarded as illustrative in 
nature and not as restrictive. 
DESCRIPTION OF THE DRAWINGS 
The accompanying draWing incorporated in and forming 
a part of the speci?cation illustrates several aspects of the 
present invention and, together With the description, serves 
to explain the principles of the invention. In the draWing: 
FIG. 1 shoWs the schematic structures of the lactone ring 
intact DB-67 (species I) and its E-ring opened counterpart 
(species II). 
FIG. 2 shoWs the dependence of solubility S (mg/mL) for 
DB-67 in aqueous solution at 25° C. on solution pH value. 
FIG. 3 shoWs the variation of solubility for the neutral 
E-ring closed DB-67 at 25° C. as a function of cyclodextrin 
concentrations (SBE-CD and HP-CD) in aqueous solution. 
FIG. 4 shoWs the variations of DB-67 concentrations for 
the neutral E-ring closed DB-67 (open circles) and overall 
DB-67 concentrations (solid circles) in the supernatant after 
1:9 dilution from an alkaline aqueous solution into 22% 
(W/v) SBE-CD as a function of time after mixing. 
FIG. 5 shoWs the DB-67 concentrations in the ?ltered 
solutions of duplicate samples after reconstitution of the 
lyophiliZed formulation. The horiZontal line indicates the 
averaged overall DB-67 concentration in the un?ltered solu 
tions. 
FIG. 6 shoWs the variations of DB-67 concentrations for 
the overall DB-67 concentrations in the supernatant after 1:9 
dilution from an alkaline aqueous solution into an acidic 
liposomal suspension (NCS 754057; provided by the 
National Cancer Institute and manufactured by Ben Venue 
Laboratories, Inc., Bedford, Ohio 44146) as a function of 
time after mixing. The horiZontal line is the overall DB-67 
concentration in the sample. 
FIG. 7 shoWs the variations of DB-67 concentrations for 
the overall DB-67 concentrations in the supernatant after 1:9 
dilution from an alkaline aqueous solution into acidic solu 
tion containing 12.5% (v/v) Cremophor EL, 12.5% (v/v) 
ethanol, and 4% (W/v) dextrose in Water as a function of time 
after mixing. The horiZontal line is the overall DB-67 
concentration in the sample. 
Reference Will noW be made in detail to the presently 
preferred embodiments of the invention, examples of Which 
are illustrated in the accompanying draWing. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As summariZed above, the present invention relates to 
novel methods for formulating lipophilic camptothecins and 
camptothecin analogues, and to compositions formulated 
thereby. The methods and compositions of the present 
invention may be accomplished by various means Which are 
illustrated in the examples beloW. These examples are 
intended to be illustrative only, as numerous modi?cations 
and variations Will be apparent to those skilled in the art. 
Our earlier studies have shoWn that precipitation occurs 
immediately during attempts to prepare a supersaturated 
solution by mechanically mixing a desired concentration 
(e.g., >1 mg/mL ?nal concentration) of lactone-intact DB-67 
drug in an organic solvent such as DMSO With a conven 
US 6,653,319 B1 
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tional dilution medium such as 20% (W/v) sulfobutyl ether 
[3-cyclodextrin (SBE-CD). This may be attributed to the high 
local concentration of the drugs in their poorly Water-soluble 
lactone form in the mixed solution. Aproper control of the 
mixing pattern (local or uniform) and rate of addition of the 
drugs in their lactone form into the dilution medium has 
therefore been key to the success of this type of formulation 
approach. HoWever, even With a controlled mixing pattern, 
formulation of a supersaturated lactone-intact DB-67 drug 
solution by simply adding a concentrated solution of the 
lactone into an aqueous solution, even in the presence of a 
suitable solubiliZing agent, results in precipitation losses of 
the drug. 
We then conceived that a supersaturated solution of a 
lipophilic camptothecin or camptothecin analog might be 
accomplished by employing a chemical approach, rather 
than a conventional mechanical approach. It has surprisingly 
been discovered that a uniform release of camptothecin and 
camptothecin analogs may be achieved by converting a 
lactone-ring opened camptothecin analog, Which has a high 
solubility in Water, to its lactone-ring closed counterpart, and 
that the rate of this chemical reaction can be regulated by 
controlling solution pH. 
It has therefore been found possible to prepare clear stable 
aqueous solutions suitable for pharmaceutical 
administration, Which Would otherWise be subject to rapid 
precipitation if other mechanical methods had been 
employed. Using the method of the present invention, aque 
ous solutions containing therapeutically useful concentra 
tions of 1—3 mg/mL camptothecin analogues and 10—40% 
(W/v) cyclodextrins may be achieved Without drug precipi 
tation. Typically, the aqueous solutions contain at least 2 
mg/mL DB-67 and 20% (W/v) [3-cyclodextrin derivatives 
such as SBE-CD or 2-hydroxypropyl [3-cyclodextrin (HP 
CD) as solubiliZing agents. 
Previously, liposomes have been utiliZed to prepare aque 
ous suspensions of pharmaceutically active camptothecins. 
HoWever, the preparation procedure is usually complex 
involving many tedious steps during Which drug loss 
(10—20%) is often found to occur. Such losses in drug 
concentration are especially dif?cult to control When the 
suspension is supersaturated With respect to the active 
component(s). UtiliZing the present invention, the liposomal 
suspension can be prepared in the absence of camptothecin 
analogues, and then mixed With a basic camptothecin solu 
tion in one ?nal step. Advantageously, this preparation 
method minimiZes the loss of the active component(s) 
during the preparation process and provides a better control 
of formulation quality. Furthermore, since the initial lipo 
somal suspension is free of camptothecin analogues, com 
mercial sources of liposomes can be used to prepare the 
liposomal formulation, loWering the cost of the manufacture 
process. UtiliZing the present method, We are successful in 
preparing stable liposomal solutions With negligible loss 
(<2%) of DB-67 during the preparation process. 
UtiliZing the present method, it is also possible to prepare 
stable solutions With other solubiliZing agents such as a 
mixture of Cremophor EL and ethanol in Water. Accordingly, 
it Will be appreciated that the present method alloWs for 
mulation of aqueous pharmaceutical preparations of poorly 
Water-soluble camptothecin analogues using a variety of 
solubiliZing agents. 
The formulation of the present invention may include a 
pharmaceutically acceptable buffer to maintain an acidic pH 
such that the camptothecin analogues are preserved in the 
active lactone form. Typically, the pH range is maintained 
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desirably beloW about 6.0, and may be regulated by any 
buffer suitable for pharmaceutical formulation. Such buffers 
include, but are not limited to, citrate, acetate, and lactate. 
Another embodiment of this invention is the lyophiliZa 
tion of the prepared aqueous solution so that the mixing 
procedure described above is conducted by manufacturer 
rather than by physician before the administration to a 
cancer patient. 
It Will be appreciated by those of skill in the art that the 
present invention provides a simple, cost-effective, and safe 
method for formulating a therapeutically useful aqueous 
solution comprising a lipophilic camptothecin or camptoth 
ecin analog. Advantageously, the compositions formulated 
by the present method may be formulated to be free of 
organic solvents (e.g., DMSO or N-methyl-2 
pyrrolidinone), in contrast to conventional methods requir 
ing use of organic solvents to solubiliZe camptothecin. 
EXAMPLES 
Set forth in greater detail beloW are speci?c details related 
to selected modes for carrying out the methods and compo 
sitions of the present invention. The examples set forth 
herein are in no Way intended to limit the scope of the 
invention. Those of skill in the art Will realiZe that, given the 
teachings provided herein, many variations of the methods 
are possible that Will fall Within the scope of the present 
invention. 
Example 1 
A clear solution comprising a DB-67 concentration of 2 
mg/mL in its lactone form and stable for at least three days 
Was prepared as folloWs. DB-67 Was accurately Weighed (20 
mg/mL) and added to a sodium hydroxide solution having a 
NaOH concentration tWice that of the drug concentration. 
The suspension Was placed on a shaker and incubated With 
shaking at 25° C. until the DB-67 Was fully dissolved. It Was 
then passed through a 0.2 pm ?lter to remove particulates. 
An aliquot of this ?ltered DB-67 basic solution Was then 
mixed With a 22.2% (W/v) SBE-CD acidic solution at a ratio 
of 1:9 (v/v). A suf?cient amount of HCl Was present in the 
?nal solution to neutraliZe the alkaline DB-67 solution. 
Citric acid (2 mM) Was included to maintain the pH of the 
?nal solution beloW 4.5. The prepared solution Was incu 
bated for tWo hours until the chemical conversion Was 
complete. 
Example 2 
Cyclodextrin/DB-67 solution Was prepared as in Example 
1, except that HP-CD Was used instead of SBE-CD. 
Example 3 
A clear solution comprising a DB-67 concentration of 1 
mg/mL in its lactone form and stable for at least three days 
Was prepared as folloWs. The DB-67 basic solution Was 
prepared as in Example 1. 
An aliquot of the ?ltered DB-67 basic solution Was mixed 
With an acidic EPL-Diluent liposomal suspension (NSC 
704057) at a ratio of 1: 19 (v/v). Immediately prior to mixing, 
a suf?cient amount of HCl Was added to the liposomal 
suspension to neutraliZe the alkaline DB-67 solution. Citric 
acid (2 mM) Was also added to the liposomal suspension to 
maintain pH of the ?nal solution at 4.4. The prepared 
solution Was incubated for tWo hours until the chemical 
conversion Was complete. 
Example 4 
A clear solution comprising a DB-67 concentration of 2 
mg/mL in its lactone form and stable for at least three hours 
US 6,653,319 B1 
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Was prepared as follows. A solution containing DB-67 and 
NaOH Was prepared as described in Example 1. An aliquot 
of the ?ltered solution Was mixed With an acidic aqueous 
cosolvent solution containing 12.5% (v/v) Cremophor EL, 
12.5% (v/v) ethanol, and 4% (W/v) dextrose at a DB-67: 
acidic aqueous cosolvent ratio of 1:9 (v/v). Immediately 
prior to mixing, a suf?cient amount of HCl to neutraliZe the 
alkaline DB-67 solution Was added. Citric acid (5 mM) Was 
added also to the solution to maintain the pH of the ?nal 
solution at 4.2. The prepared solution Was incubated for tWo 
hours until the chemical conversion Was complete. 
Example 5 
The ?nal solution prepared as described in Example 1 Was 
lyophiliZed in a glass vial and sealed With a rubber stopper 
and aluminum cap for long-term storage. The lyophiliZed 
preparation may be reconstituted With sterile Water for 
administration orally or by a parenteral route to a cancer 
patient. 
Example 6 
Solubilities of DB-67 or camptothecin in a given solvent 
system Were determined by adding an amount of the drugs 
Well in excess of its estimated solubility to 1—2 mL of the 
desired solvent in a 4-mL glass vial. The capped vial Was 
rotated in a VWR2010 incubator set at 25° C. for a period 
of 3—15 days. The sample Was then passed through a 0.45 
pm ?lter, except for liposome or emulsion samples, Which 
Were passed through a 1.2 pm ?lter. The collected sample 
Was Weighed, diluted With methanol, and analyZed by 
HPLC. The HPLC system consisted of a Discovery C18 15 
cm><4.6 mm column and a Discovery C18 2 cm><4.6 mm 5 
pm guard column (Supelco), a Beckman 110B solvent 
delivery module, a Rheodyne M7125 injector With a 20 pm 
injection loop (Rainin), a Waters M2487 Dual )1 Absorbance 
detector set at 254 nm, an HP 3392A integrator, and a mobile 
phase of 25% and 41% (v/v) acetonitrile in 2% (W/v) 
triethylamine acetate for camptothecin and DB-67, respec 
tively. 
The solubility results for DB-67 in various solvent sys 
tems are summariZed in Table 1. The solubility-pH pro?le 
for DB-67 in aqueous solution is presented in FIG. 2, Where 
the curve is a non-least-squares ?t using an equilibrium 
model for the base-catalyZed lactone-ring opening and ion 
iZation of substituents in DB-67 (10-OH and the —COOH 
When the lactone-ring is opened at a basic pH). As noted, the 
solubility of DB-67 in an aqueous solution of acidic pH 
(5.2), Where DB-67 exists mostly in E-ring intact form, is 
0.11 pg/mL, Well beloW the target dosage of 2 mg/mL to 
maintain an appropriate administration time and volume. 
Various solubiliZation approaches such as cosolvents, com 
plexation With Water-soluble cyclodextrins (e.g., SBE-CD 
and HP-CD), emulsions, and liposomes failed to accomplish 
the desired dosage for DB-67 of 1—2 mg/mL. 
As also shoWn in Table 1 and FIG. 2, a solubility of ~18 
mg/mL can be accomplished in an aqueous solution of pH 
>10.2. HoWever, as noted above the ioniZed (alkaline) 
DB-67 exists mostly in the lactone-ring opened 
(carboxylated) form. Previous studies on other camptothecin 
analogues indicate that the lactone-ring opened species of a 
camptothecin analogue is therapeutically inactive, has a 
signi?cantly shorter plasma half life, and exhibits greater 
toxicity than the lactone-ring intact species. This is sup 
ported by pharmacologic evidence from clinical studies in 
humans and other mammalian species receiving sodium 
camptothecin, 9-amino camptothecin and Topotecan. 
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Desirably, the present invention alloWs formulation of super 
saturated pharmaceutical formulations With the required 
dosage for the lactone-ring intact DB-67 Which are stable 
With respect to precipitation Within an appropriate time 
period of administration (e.g., <24 hours). 
TABLE 1 
Solubilities of DB-67 in various solvent systems at 250 C.3 
Solvent S (mg/mL) 
Water/30 mM acetate buffer at pH 5.23 
Water/0.5 M carbonate buffer at pH 10.20 
40% (W/v) HPCD/Water 
40% (W/v) SBE-CD/Water/l mM HCl 
40% PG, 10% (v/v) EtOH/Water 
10% (v/v) PEG-400/Water 
50% (v/v) PEG-400/Water 
Emulsion (20% soybean oil, 2% glycerin, 73% 
Water, 4% TWeen80, 1% eggPC) 
Liposome (70:25:5 (mole) DMPC:Chol:DMPG) 
50% Cremophor, 50% (v/v) EtOH (Diluent-12) 
5% Cremophor, 5% (v/v) in 5% (W/v) 
Dextrose/Water 
(1.11 1 0.00) X 1075 
1.78 X 10*1 
(4.9 1 0.2) X 10*1 
(2.09 1 0.04) X 1071 
(1.73 1 0.04) X 1071 
(3.3 r 0.5) x 10’2 
(2.0 1 0.3) X 10*1 
(2.06 1 0.05) X 1071 
(7.4 1 0.3) X 10*3 
(7.5 r 0.2) x 100 
2.00 X 1071 
3mean 1 standard deviation from duplicate samples except in 10% (v/v) 
diluent-12 in 5% (W/v) dextrose/Water and Water/0.5 M carbonate buffer at 
pH 10.20 (single). 
The results summariZed in Table 1 indicate that DB-67 
can be substantially solubiliZed in the presence of[3 
cyclodextrins (e.g., SBE-CD and HP-CD). Cyclodextrins 
are cyclic oligosaccharides With a hydrophobic cavity in the 
center. The most common cyclodextrins are 01-, [3, 
y-cyclodextrins, consisting of 6, 7, and 8 ot-1,4-linked glu 
cose units, respectively. With recent development of manu 
facturing technology, Water-soluble cyclodextrin derivatives 
formed, by alkylation or hydroxyalkylation of the primary 
hydroxyl groups in cyclodextrins have become less 
expensive, and are Widely used in solubiliZation and stabi 
liZation of various drug agents because of their capability to 
form inclusion complexes With drug molecules having siZe 
compatible With the dimensions of the cyclodextrin cavity. 
As a second characteriZation step, the solubiliZation mecha 
nisms for selected [3-cyclodextrins (SBE-CD and HP-CD) 
are investigated, as described beloW (Example 7). 
Example 7 
To understand the complexation mechanisms behind this 
solubiliZation effect, a solubility method Was employed to 
determine the formation constant betWeen a camptothecin 
analogue and a cyclodextrin derivative. In the solubility 
experiment, the solution pH Was controlled beloW 4.6 With 
a 30 mM citrate buffer. As shoWn in FIG. 3, the linear 
solubility pro?le for DB-67 complexation With SBE-CD 
indicates a predominant formation of 1:1 complexation 
betWeen the neutral E-ring closed DB-67 and SBE-CD. In 
contrast, a quadratic dependence of DB-67 solubility on 
cyclodextrin concentration Was observed for complexation 
of the E-ring closed DB-67 With HP-CD, suggesting more 
1:2 complexes at a higher HP-CD concentration. 
In the limit of [CD]>>SO, the relevant formation constants 
can be expressed as: 
Where S0 is the solubility in the absence of cyclodextrins, 
1:1 and 12 are the 1:1 and 1:2 complex formation 
constants, and [CD] is concentration of cyclodextrin. A 
linear least-squares ?t of the data for SBE-CD as shoWn in 
FIG. 3 yields the complex formation constant of Kfm= 
US 6,653,319 B1 
8.5:0.2><103M_1(r2=0.999). The linear behavior also sug 
gests that only 1:1 complexes between the neutral E-ring 
intact DB-67 and SBE-CD are favorable. The inability for 
SBE-CD to form 1:2 complexes With DB-67 apparently 
arises from the presence of an average of seven negatively 
charged sulfobutyl ether groups in a SBE-CD molecule 
preventing the approach of tWo SBE-CDs to each other to 
form 1:2 complexes. A least-squares ?t of the data for 
HP-CD as shoWn in FIG. 3 according to Equation 1 yields 
the 1:1 and 1:2 complex formation constants of 1‘1= 
5.8:0.2><103M_1 and Kf1‘1=3.8:0.2 ><104M_1(r2=1.000). The 
ability of HP-CD to form 1:2 complexes With the E-ring 
intact DB-67 suggests that there, are at least tWo binding 
sites in the E-ring intact DB-67. 
One of the key discoveries in the present invention is the 
utility of the hydrolysis reaction betWeen the lactone-closed 
and lactone-opened species (I and II in FIG. 1) to sloWly and 
uniformly release lactone-closed camptothecins in a dilution 
medium in order to prevent the precipitation of the active 
camptothecin analogues and maintain the physical stability 
of the formulation. Furthermore, cyclodextrins can not only 
solubiliZe camptothecin analogues in Water but also poten 
tially sloW doWn the E-ring opening hydrolysis reaction in 
vivo increasing the lifetime of the drugs in human blood. 
Thus, it is necessary to investigate the hydrolysis kinetics of 
camptothecin analogues in solution. 
Example 8 
The reaction kinetics for the E-ring opened and closed 
DB-67 Were investigated in aqueous solutions at pH 7.4 and 
4.0, respectively. The reactions Were thermostated at 
25:0.1° C. by a circulation Water bath and initiated by 
adding 0.1 mL of reactants (Species I DB-67 in DMSO or 
Species II DB-67 in 2 mM NaOH; see FIG. 1) to a 30 mM 
phosphate or acetate buffer solution With an initial reactant 
concentration of 2—4><10_6 M. After the addition and at 
different time intervals, aliquots of the reaction solutions 
Were WithdraWn and immediately assayed by HPLC. The 
concentrations of both species I and II Were monitored in 
order to evaluate the mass balance and other possible 
degradation products. Simultaneous non-linear least-squares 
?ts of the kinetic pro?les yield the ?rst-order rate constants 
for the lactone-ring opening and closing processes of k 
1.1:0.1><10_4 s-1 and kCl0Se=3.3:0.3><10_4 s_1. The mass 
balance results indicate that no other reaction processes 
contribute signi?cantly to the variation of concentrations for 
species I and II DB-67. 
We have also investigated the hydrolysis processes for the 
lactone-ring intact DB-67 (Species I) at pH 7.4 in the 
presence of 20% (W/v) SBE-CD and HP-CD, respectively. 
The temporal pro?les for the disappearance of species I and 
the appearance of species II Were found to folloW the 
?rst-order kinetic models similar to those in the absence of 
cyclodextrins. The ?tted rate constants are k0pm=(7.1:0.1)>< 
1045-1 and k0pm=(6.2:0.1)><10_5s_1 for 20% (W/v) SBE 
CD and HP-CD, respectively. As noted above, the presence 
of 20% (W/v) SBE-CD or HP-CD reduces the rate for the 
lactone-ring opening process by 1.6- and 1.8-fold, respec 
tively. The rate reduction is therefore more marked in the 
presence of HP-CD. 
The mechanisms responsible for the improved stability of 
the therapeutically viable DB-67 may therefore be different 
for use of the solubiliZing agents SBE-CD and HP-CD. In 
the case of 20% (W/v) HP-CD, more than 99.9% of DB-67 
are included in the CD hydrophobic cavity, among Which 
roughly 46% of the complexes are in the form of 1:2 
complexes. If the hydrolysis site on the E-ring is included in 
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the CD cavity in the 1:2 complexes With HP-CD but not in 
the 1:1 complexes, the E-rings in only about 46% DB-67 are 
protected from the attack by OH' ions. While not Wishing to 
be bound by any particular theory, this may explain the 
approximately 44% reduction in the observed rate constant. 
On the other hand, in the presence of 20% (W/v) SBE-CD, 
more than 99.8% of DB-67 are bound to SBE-CD forming 
the predominantly 1:1 complexes. Although there perhaps 
are a small fraction of 1:1 complexes Where the hydrolysis 
site on the lactone-ring is included in the CD cavity, the 
presence of the negatively charged sulfobutyl ether groups 
in SBE-CD may repel the surrounding OH- ions and reduce 
the rate for OH' catalyZed hydrolysis reaction. 
The signi?cantly reduced rate of hydrolysis to the car 
boxylate form in the presence of [3-cyclodextrin derivatives 
suggests an additional bene?t of the cyclodextrin formula 
tions revealed in this invention. The stability of camptoth 
ecin analogues in their active lactone form in vivo may 
accordingly also increase the half-life of the drugs in human 
blood, potentially improving bioavailability and therapeutic 
usefulness. 
Example 9 
A successful pharmaceutical formulation With a super 
saturated drug concentration requires a physical stability 
With respect to drug precipitation. In our ?rst attempt, 20—25 
mg/mL of DB-67 Was loaded in DMSO because of the 
drug’s high solubility in this solvent. The dissolved DB-67 
Was then added sloWly to a 20% (W/v) SBE-CD aqueous 
solution by a volume ratio of 1:9 to achieve a ?nal drug 
concentration of 2 mg/mL. The dilution rate Was maintained 
at 0.10 mL/min. It Was found that the precipitation occurred 
even during the mixing process and continued after the 
?nish of mixing. Since, DB-67 exists in the lactone-ring 
intact form in DMSO, Which has a very loW solubility in 
Water, the local drug concentration near the mixing region is 
so large that it is dif?cult to prevent the drugs from under 
going fast nucleation and precipitation. Aproper control of 
the release pattern (local or uniform) and rate of DB-67 into 
the dilution medium is therefore critical to the success of this 
type of formulation approach. 
As described above, a sloW and uniform release of DB-67 
into a dilution medium may be accomplished by employing 
a chemical approach, namely by converting the E-ring 
opened DB-67 (Species II, see FIG. 1), Which is highly 
Water-soluble, to the neutral E-ring closed DB-67 (Species I) 
in a controlled fashion. Studies on other camptothecin 
analogs suggest that the rate of this chemical reaction can be 
regulated by solution pH. Accordingly, 20 mg/mL of DB-67 
Was loaded in a sodium hydroxide solution With NaOH 
concentration maintained at tWice that of the drug concen 
tration. The prepared DB-67 alkaline aqueous solution Was 
passed through a 0.2 pm ?lter before it Was added sloWly 
(0.11 mL/min) into 20% (W/v) acidic SBE-CD solution by a 
volume ratio of 1:9. In order to completely neutraliZe 
DB-67, HCl Was present in the dilution solution in an 
amount equal to the amount of NaOH in the DB-67 alkaline 
solution. A small amount of acetate buffer (5 mM) Was also 
included in the dilution medium to control the solution pH 
to about 4 in order to facilitate a timely conversion from the 
E-ring opened DB-67 to its E-ring closed counterpart. 
FIG. 4 shoWs the overall DB-67 concentration and the 
concentration of converted lactone-intact DB-67 in the solu 
tion at different time intervals. Overall DB-67 concentration 
remained constant over an extended period of three days, 
exceeding the target stability time of less than one day. At 
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the measured solution pH of 4.4, the E-ring closed DB-67 
slowly built up in the ?nal solution in a uniform manner and 
the process Was nearly complete Within 100 minutes. This 
sloW and uniform build-up of the lactone-ring intact DB-67 
may explain the superior stability of this formulation 
approach in comparison With the simple mechanical method 
using DMSO as a solubiliZing agent. 
Example 10 
For long-term storage, the ?nal solution containing 20% 
(W/v) SBE-CD and about 2 mg/mL lactone-ring intact 
DB-67 prepared according to the procedure described above 
Was lyophiliZed after the chemical conversion process Was 
nearly completed (>90%). Shortly after the lyophiliZation, 
the lyophiliZed sample Was reconstituted and the stability of 
the reconstituted solution Was examined folloWing the same 
procedure as described above. The results are presented in 
FIG. 5. The reconstituted solution Was stable for about seven 
days, suggesting that no signi?cant occurrence of 
nucleation/precipitation during the lyophiliZation process 
and Within about seven days after reconstitution. 
Example 11 
The precipitation pro?les of DB-67 solutions containing 
other solubiliZing agents such as liposomes and an acidic 
aqueous cosolvent solution comprising an equal volume 
mixture of ethanol and cremophor, prepared as described in 
Examples 3 and 4, respectively, Were evaluated. The stabil 
ity pro?les are presented in FIGS. 6 and 7. The liposome/ 
DB-67 solutions Were stable for more than three days (FIG. 
6). The acidic aqueous cosolvent/DB-67 solutions Were 
stable for more than three hours. Dynamic light scattering 
measurements indicated that the average particle siZe in the 
acidic liposomal suspensions (pH 2.1 and 4.6) remained in 
a narroW range of 74—79 nm during ?ve days’ incubation, 
suggesting that the acidic liposomal suspension is stable for 
at least ?ve days (FIG. 6). 
The foregoing description of preferred embodiments of 
the invention has been presented for purposes of illustration 
and description. It is not intended to be exhaustive or to limit 
the invention to the precise form disclosed. Obvious modi 
?cations or variations are possible in light of the above 
teachings. The embodiments Were chosen and described to 
provide the best illustration of the principles of the invention 
and its practical application to thereby enable one of ordi 
nary skill in the art to utiliZe the invention in various 
embodiments and With various modi?cations as are suited to 
the particular use contemplated. All such modi?cations and 
variations are Within the scope of the invention as deter 
mined by the appended claims When interpreted in accor 
dance With the breadth to Which they are fairly, legally and 
equitably entitled. 
What is claimed is: 
1. Amethod for preparing a stable supersaturated aqueous 
solution of a lipophilic camptothecin or a camptothecin 
analog, comprising formulating an alkaline solution of said 
lipophilic camptothecin or camptothecin analog, and acidi 
fying said alkaline solution in the presence of a solubiliZing 
agent. 
2. The method of claim 1, Wherein said alkaline solution 
is formulated to have a pH of at least 10.0. 
3. The method of claim 1, Wherein said alkaline camp 
tothecin or camptothecin analog is acidi?ed by diluting said 
alkaline solution into an acidic solution in the presence of a 
solubiliZing agent to achieve a ?nal pH of up to about 6.0. 
4. The method of claim 3, Wherein said acidic solution 
includes a buffer suitable for maintaining a pH of said acidic 
solution at up to about 6.0. 
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5. The method of claim 4, Wherein said buffer is selected 
from the group of buffers consisting of citrate, acetate, 
lactate, and any mixture thereof. 
6. The method of claim 1, Wherein said solubiliZing agent 
is selected from the group consisting of a cyclodextrin, a 
liposome, a thermodynamically stable colloidal dispersion, 
an emulsion, and any mixture thereof. 
7. The method of claim 6, Wherein said cyclodextrin is a 
Water-soluble [3-cyclodextrin derivative. 
8. The method of claim 7, Wherein said Water-soluble 
[3-cyclodextrin derivative is selected from the group con 
sisting of sulfobutyl ether [3-cyclodextrin, 2-hydroxypropyl 
[3-cyclodextrin, and any mixture thereof. 
9. The method of claim 6, Wherein said liposome is 
formulated as an acidic liposomal suspension having a pH of 
up to about 6.0. 
10. The method of claim 6, Wherein said thermodynami 
cally stable colloidal dispersion is formulated to have a pH 
of up to about 6.0. 
11. The method of claim 10, Wherein said thermodynami 
cally stable colloidal dispersion comprises a surfactant lipid. 
12. The method of claim 11, Wherein said surfactant lipid 
is selected from the group consisting of Cremophor, Vitamin 
E TGPS, polyethylene oxide/polypropylene oxide polymers, 
TWeen 80, and any mixture thereof. 
13. The method of claim 11, Wherein said thermodynami 
cally stable colloidal dispersion includes a Water miscible 
co-solvent selected from the group consisting of ethanol, 
polyethylene glycol, polypropylene glycol, glycerol, and 
any mixture thereof. 
14. The method of claim 11, Wherein said thermodynami 
cally stable colloidal dispersion includes an agent for adjust 
ing tonicity selected from the group consisting of dextrose, 
sodium chloride, and any mixture thereof. 
15. The method of claim 1, Wherein said lipophilic 
camptothecin or camptothecin analog is selected from the 
group consisting of camptothecin, silatecan 7-t 
butyldimethylsilyl-10-hydroxycamptothecin, 10-hydroxy-7 
ethyl camptothecin, 9-nitrocamptothecin, silatecan 7-t 
butyldimethylsilyl camptothecin, 7-methylcamptothecin, 
7-ethylcamptothecin, 7-propylcamptothecin, 
7-butylcamptothecin, and any mixture thereof. 
16. A method for preparing a stable supersaturated aque 
ous solution of a lipophilic camptothecin or a camptothecin 
analog, comprising the steps of: 
solubiliZing said camptothecin or camptothecin analog in 
an alkaline solution; and 
diluting said alkaline solution containing said solubiliZed 
camptothecin or camptothecin analog into an acidic 
solution in the presence of a solubiliZing agent. 
17. The method of claim 16, Wherein said solubiliZing 
agent is added to said alkaline solution of camptothecin or 
camptothecin analog prior to diluting the alkaline solution 
into the acidic solution. 
18. The method of claim 16, Wherein said alkaline solu 
tion has a pH of at least about 10.0. 
19. The method of claim 16, Wherein said alkaline solu 
tion is diluted into said acidic solution to achieve a ?nal pH 
of up to about 6.0. 
20. The method of claim 16, Wherein said acidic solution 
includes a buffer suitable for maintaining a ?nal pH in said 
acidic solution of up to about 6.0. 
21. The method of claim 20, Wherein said buffer is 
selected from the group of buffers consisting of citrate, 
acetate, lactate, and any mixture thereof. 
22. The method of claim 16, Wherein said solubiliZing 
agent is selected from the group consisting of a cyclodextrin, 
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a liposome, a thermodynamically stable colloidal dispersion, 
an emulsion, and any mixture thereof. 
23. The method of claim 22, Wherein said cyclodextrin is 
a Water-soluble [3-cyclodextrin derivative. 
24. The method of claim 23, Wherein said Water-soluble 
[3-cyclodextrin derivative is selected from the group con 
sisting of sulfobutyl ether [3-cyclodextrin, 2-hydroxypropyl 
[3-cyclodextrin, and any mixture thereof. 
25. The method of claim 22, Wherein said liposome is 
formulated as an acidic liposomal suspension having a pH of 
up to about 6.0. 
26. The method of claim 22, Wherein said thermodynami 
cally stable colloidal dispersion is formulated to have a pH 
of up to about 6.0. 
27. The method of claim 26, Wherein said thermodynami 
cally stable colloidal dispersion comprises a surfactant lipid. 
28. The method of claim 27, Wherein said surfactant lipid 
is selected from the group consisting of Cremophor, Vitamin 
E TGPS, polyethylene oxide/polypropylene oxide polymers, 
TWeen 80, and any mixture thereof. 
29. The method of claim 26, Wherein said thermodynami 
cally stable colloidal dispersion includes a Water miscible 
co-solvent selected from the group consisting of ethanol, 
polyethylene glycol, polypropylene glycol, glycerol, and 
any mixture thereof. 
30. The method of claim 26, Wherein said thermodynami 
cally stable colloidal dispersion includes an agent for adjust 
ing tonicity selected from the group consisting of dextrose, 
sodium chloride, and any mixture thereof. 
31. The method of claim 16, Wherein said lipophilic 
camptothecin or camptothecin analog is selected from the 
group consisting of camptothecin, silatecan 7-t 
butyldimethylsilyl-10-hydroxycamptothecin, 10-hydroxy-7 
ethyl camptothecin, 9-nitrocamptothecin, silatecan 7-t 
butyldimethylsilyl camptothecin, 7-methylcamptothecin, 
7-ethylcamptothecin, 7-propylcamptothecin, 
7-butylcamptothecin, and any mixture thereof. 
32. The method of claim 16, further including the step of 
lyophiliZing the stable, supersaturated solution for storage. 
33. A composition for the treatment of a cancer in an 
animal, comprising an aqueous solution containing a thera 
peutically sufficient amount of a lipophilic camptothecin or 
camptothecin analog formulated by the steps of solubiliZing 
said camptothecin or camptothecin analog in an alkaline 
solution, and diluting said alkaline solution into an acidic 
solution in the presence of a solubiliZing agent. 
34. The composition of claim 33, Wherein said lipophilic 
camptothecin or camptothecin analog is selected from the 
group consisting of camptothecin, silatecan 7-t 
butyldimethylsilyl-10-hydroxycamptothecin, 10-hydroxy-7 
ethyl camptothecin, 9-nitrocamptothecin, silatecan 7-t 
butyldimethylsilyl camptothecin, 7-methylcamptothecin, 
7-ethylcamptothecin, 7-propylcamptothecin, 
7-butylcamptothecin, and any mixture thereof. 
35. The composition of claim 33, Wherein said solubiliZ 
ing agent is selected from the group consisting of a 
cyclodextrin, a liposome, a thermodynamically stable col 
loidal dispersion, an emulsion, and any mixture thereof. 
36. The composition of claim 35, Wherein said cyclodex 
trin is a Water soluble [3-cyclodextrin derivative. 
37. The composition of claim 36, Wherein said Water 
soluble [3-cyclodextrin derivative is selected from the group 
consisting of sulfobutyl ether [3-cyclodextrin, 
2-hydroxypropyl [3-cyclodextrin, and any mixture thereof. 
38. The composition of claim 35, Wherein said liposome 
is formulated as an acidic.liposomal suspension having a pH 
of up to about 6.0. 
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39. The composition of claim 35, Wherein said thermo 
dynamically stable colloidal dispersion is formulated to have 
a pH of up to about 6.0. 
40. The composition of claim 39, Wherein said thermo 
dynamically stable colloidal dispersion comprises a surfac 
tant lipid. 
41. The composition of claim 40, Wherein said surfactant 
lipid is selected from the group consisting of Cremophor, 
Vitamin E TGPS, polyethylene oxide/polypropylene oxide 
polymers, TWeen 80, and any mixture thereof. 
42. The composition of claim 39, Wherein said thermo 
dynamically stable colloidal dispersion includes a Water 
miscible co-solvent selected from the group consisting of 
ethanol, polyethylene glycol, polypropylene glycol, 
glycerol, and any mixture thereof. 
43. The composition of claim 39, Wherein said thermo 
dynamically stable colloidal dispersion includes an agent for 
adjusting tonicity selected from the group consisting of 
dextrose, sodium chloride, and any mixture thereof. 
44. The composition of claim 33, Wherein said lipophilic 
camptothecin or camptothecin analog is included in an 
amount of from about 0.5 to about 3 mg/mL of solution. 
45. The composition of claim 35, Wherein said cyclodex 
trin solubiliZing agent is included in an amount of from 
about 10% to about 40% W/v. 
46. The composition of claim 35, Wherein said liposome 
solubiliZing agent is included in an amount of from about 
10% to about 40% W/v. 
47. The composition of claim 35, Wherein said thermo 
dynamically stable colloidal dispersion comprises-an aque 
ous solution of about 12.5% v/v Cremophor EL and 12.5% 
v/v ethanol. 
48. The composition of claim 34, Wherein said camptoth 
ecin analogue is silatecan 7-t-butyldimethylsilyl-10 
hydroxycamptothecin. 
49. The composition of claim 38, Wherein said acidic 
liposomal suspension includes lipids selected from the group 
consisting of egg phospholipids, cholesterol, 
dimyristoylphosphatidylcholine, 
dimyristoylphosphatidylglycerol, and any mixture thereof. 
50. The composition of claim 33, Wherein said acidic 
solution comprises an amount of an acid suitable for neu 
traliZing said alkaline camptothecin or camptothecin analog 
solution. 
51. The composition of claim 50, Wherein said acid is 
selected from the group consisting of hydrochloric acid, 
phosphoric acid, carbonic acid, formic acid, acetic acid, 
lactic acid, citric acid, and any mixture thereof. 
52. The composition of claim 33, Wherein said alkaline 
solution includes an amount of base double the amount of 
camptothecin or camptothecin analog. 
53. The composition of claim 52, Wherein said base is 
selected from the group consisting of sodium hydroxide, 
potassium hydroxide, sodium carbonate, and any mixture 
thereof. 
54. The composition of claim 33, Wherein said acidic 
solution includes a-buffer suitable for maintaining a pH of 
the acidic solution at up to about 6.0. 
55. The composition of claim 54, Wherein said buffer is 
selected from the group of buffers consisting of citrate, 
acetate, lactate, and any mixture thereof. 
* * * * * 
